Results 31 to 40 of about 47,030 (243)

Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?

open access: yesFrontiers in Immunology, 2020
The coronavirus disease 2019 (COVID-19) pandemic is a worldwide threatening health issue. The progression of this viral infection occurs in the airways of the lungs with an exaggerated inflammatory response referred to as the “cytokine storm” that can ...
A. Khalil, Amina Kamar, G. Nemer
semanticscholar   +1 more source

Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments

open access: yesFront. Cell Dev. Biol., 2019
Neuroinflammation is initiated when glial cells, mainly microglia, are activated by threats to the neural environment, such as pathogen infiltration or neuronal injury.
Y. Jung   +3 more
semanticscholar   +1 more source

Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports

open access: yesRevista da Sociedade Brasileira de Medicina Tropical, 2020
INTRODUCTION: Thalidomide is an anti- tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL).
Pugazhenthan Thangaraju   +4 more
doaj   +1 more source

Augmentation of Pectoral Fin Teratogenicity by Thalidomide in Human Cytochrome P450 3A-Expressing Zebrafish

open access: yesPharmaceuticals, 2023
The pharmacological and toxicological effects of active metabolites of enzymes including cytochrome P450 (CYP) are important. While it has been believed for a long time that thalidomide causes characteristic limb malformation only in rabbits and primates
Wenjing Dong   +8 more
doaj   +1 more source

The Use of Thalidomide in Steroid Dependent Continous Erythema Nodosum Leprosum Leprosy Patient: A Case Report

open access: yesBerkala Ilmu Kesehatan Kulit dan Kelamin (Periodical of Dermatology and Venerology), 2016
Background: Treatment thalidomide in erythema nodosum leprosum (ENL), can inhibits the transcription repression mediated by tumor necroting factor (TNF). Thalidomide can be used as sparing agents drug to reduce the dependency of steroid.
Dian Pertiwi Habibie   +1 more
doaj   +1 more source

Synergistic anti-allodynic effect between intraperitoneal thalidomide and morphine on rat spinal nerve ligation-induced neuropathic pain [PDF]

open access: yesKorean Journal of Anesthesiology, 2013
BackgroundThalidomide has been recognized as having an anti-allodynic effect against neuropathic pain induced by spinal nerve ligation. Its clinical beneficial effects are mainly derived from its immune-modulating property, which is known to influence ...
Hyung Gon Lee   +4 more
doaj   +1 more source

Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4

open access: yesScientific Reports, 2020
Exposure to thalidomide during a critical window of development results in limb defects in humans and non-human primates while mice and rats are refractory to these effects. Thalidomide-induced teratogenicity is dependent on its binding to cereblon (CRBN)
David G. Belair   +5 more
semanticscholar   +1 more source

Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3

open access: yesAdvanced Science, EarlyView.
In MASLD, YTHDC1 undergoes increased lactylation and ubiquitination, reducing its expression. AARS1 mediates lactylation at lysine 565, while disrupted binding to LDHA further promotes lactylation, suppressing YTHDC1. This downregulation enhances PTPN22 mRNA stability, leading to NLRP3 dephosphorylation and activation, which exacerbates inflammation ...
Feng Zhang   +16 more
wiley   +1 more source

Thalidomide induced impotence in male hematology patients: a common but ignored complication?

open access: yesHaematologica, 2007
Thalidomide has become an important agent in the treatment of myeloma. However, thalidomide induced erectile dysfunction is a serious complication which has received very little attention. In our hematology department, 6 out of 11 male patients developed
Philip T. Murphy, John Rory O’Donnell
doaj   +1 more source

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy